About 25 million Americans live with a rare, undiagnosed condition, yet most clinical trial recruitment infrastructure assumes patients already have a confirmed diagnosis in hand. That mismatch is the operational problem that makes undiagnosed populations so persistently underrepresented in research, and it starts well before a site ever opens a screening log.
The practical gap is wide. European data put the average time to diagnosis for rare disease patients at 4.7 years, with 56 percent still undiagnosed more than six months after first medical contact. Patients who arrive at a trial site after that kind of experience often carry layers of accumulated frustration: repeated inconclusive testing, clinicians who moved on when obvious explanations ran out, and sometimes a wrong diagnosis that shaped years of treatment. A young adult labeled with IBS, for example, may have colorectal cancer that was never pursued because age made it seem improbable. Recruitment teams that treat the listed diagnosis as settled will miss those patients entirely.
Cost is a concrete barrier before any of the relationship dynamics come into play. Uninsured or underinsured patients frequently cannot access the biopsies, genomic panels, or cancer screenings that would even make them eligible for a study. Sponsors that cover diagnostic testing during screening widen the pool directly, not just symbolically. Once patients are engaged, scheduling flexibility and travel reimbursement matter too, but those measures address retention problems that follow from an enrollment problem that cost solved first. A separate risk appears at the other end of screening: when a participant learns for the first time during the trial process that they have a serious disease, the site needs social services available immediately, not as an afterthought. A diagnosis that closes one uncertainty opens others, and sites unprepared for that moment can lose a participant who felt abandoned at the hardest point.
Mayo Clinic data suggest roughly 70 percent of unexplained genetic disorders still go unsolved even at a major academic center, which means the population available to trials is far larger than diagnosed patient registries reflect. The single clearest indicator of whether a sponsor has accounted for this: whether the trial’s screening budget includes coverage for diagnostic tests, because that decision, made in planning, determines how many eligible patients the protocol can actually reach.
Source link: https://www.medpace.com/blog/four-key-considerations-for-recruiting-an-undiagnosed-population/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
